anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Using the software, 3D digitized mandible will be virtually repositioned in ideal centric relation through accurate adjustment of the condyle in its glenoid fossa. Patients' dental casts will be scanned, and digitized into a virtual 3D model and superimposed to the CT cuts into the virtual plan software environment in order to produce preoperative CAD/CAM splint on the adjusted centric occlusion. Patients will be instructed to wear the splints continuously for 3 months, only being allowed to remove them when eating and brushing their teeth.
Participants receiving BEMER therapy laid supine on the BEMER mat (BEMER International AG). The BEMER was set at intensity 3 for week 1, intensity 4 for week 2, and intensity 5 for week 3. The B.Pad (BEMER International AG) was placed under their cervical region. B.Pad® settings were set at Program 1 (8 minutes long) in week 1 through week 3. These settings were selected based on the manufacturer's recommendations.
The role of non-coding RNAs in regulating biological processes associated with cancer progression, such as proliferation, migration, and apoptosis, has been extensively studied. Long non-coding RNAs (lncRNAs) play a role in regulating these processes through various mechanisms, including transcriptional and post-transcriptional modifications. In post-transcriptional regulation, lncRNAs can bind to specific miRNAs and affect their function, which can either promote or inhibit cancer development. The interaction between lncRNAs, miRNAs, and mRNAs forms a network known as competitive endogenous RNA (ceRNA), which is involved in cancer progression or inhibition. One specific miRNA called miR-26a-5p has been identified as having tumor-suppressive properties. However, when lncRNAs bind to and inhibit miR-26a-5p, it can lead to cancer progression. Therefore, targeting this ceRNA network could be a promising strategy for preventing cancer development. This review will first discuss the anticancer effects of miR-26a-5p and then explore the involvement of the lncRNA-miR26a-5p-mRNA axis in cancer progression and potential targeted therapies.
Deep repetitive Transcranial Magnetic Stimulation will be applied to the insula for 30 minutes. This will consist of 34 trains each comprising of 30 pulses at 10Hz. The inter-train interval is 3 seconds. The intervention is followed by radiotracer and PET.
After baseline evaluations, insulin detemir will be given at bedtime and titrated to achieve a fasting plasma glucose between 80-100 mg/dl. After 3 months patients will be admitted to assess the metabolic effects of intervention. After this, insulin aspart (insulin detemir plus aspart) will be added before breakfast, lunch and dinner titrated to normalize the postprandial plasma glucose. After another 3 months patients are readmitted and all study procedures repeated. This group will receive Insulin detemir and pre-meal insulin aspart.
Said invention is a unique modi or set of immunological techniques/methods, by which to develop various types of infertility vaccines, primarily designed to reduce fertility or to produce infertility in animals and/or in humans. Said reduced fertility or infertility may be permanent or exists with variable duration. The immunological infertility responses, resulting from said uniquely developed vaccines (as affected/created by the proposed methodologies), may be superior to currently existing infertility vaccines {referenced, herein}, since they (the vaccines resulting from the proposed methods, herein) would contain a far greater diversity/variety of antigens; and are therefore, considered as polyantigenic vaccines, herein. A larger diversity/variety of antigens may better elicit a greater diversity/variety of endogenous antibodies. A greater variety of antibody types and antibody variable sites may enhance the infertility response. 
     Correspondingly, the proposed methods may result in infertility vaccines which affect greater numbers and types of memory cells. While currently existing infertility vaccines use individual or limited numbers of identified antigens to sperm, or to sex-related hormones, etc. Said proposed modi or set of methods are unique, not only because they are polyantigenic, but because of some of the specified antigenic sources employed, besides sperm, i.e., ova, gamete germinal cells, gamete precursor cells, male ejaculate, liquor folliculi, certain differentiated stem cells, etc. The proposed modi does not use isolated/identified sperm antigens, as is currently used in infertility vaccines. Heretofore, the proposed modi has not been proposed. 
     Because humans and many domesticated animals (cats, dogs, cattle, sheep, birds, etc.) are such out-bred species, in that they may possess a broad variety of gamete-based antigens, individual responsiveness to an immunologic vaccine which uses a single or highly limited number (one or two) of isolated/identified antigens, is apt to be ineffective. Limited antigen types may fail to adequately address the vaccine recipient's own gamete-based antigens. The use of the proposed polyantigenic modi may enhance vaccine efficacy by providing a greater diversity of antigens, and thereby affecting a broader spectrum of response antibodies, etc.
<P>PROBLEM TO BE SOLVED: To provide a pasting sheet or tape, while keeping the adhering property and close contacting property with the skin, etc., as soft, giving extremely low pain and peeling off of the keratin on peeling it off, hardly causing skin irritation or skin disturbance and also excellent in anchoring property to a supporting material.  <P>SOLUTION: This sheet or tape consisting of a thermoplastic elastomer of an ABA type block copolymer obtained by mixing 1 kind or ≥2 kinds of polymers selected from a group consisting of a styrene-isoprene-styrene block copolymer, a styrene-butadiene-styrene block copolymer, a styrene-ethylene-styrene block copolymer and a styrene-butylene-styrene block copolymer, a liquid component having compatibility with the thermoplastic elastomer and an elastic material having sticky property including a tackifier is characterized by containing 20.5-40 wt. % thermoplastic elastomer, 20-59.5 wt. % liquid component and 0.5-59.5 wt. % tackifier.  <P>COPYRIGHT: (C)2004,JPO
BACKGROUND: Fetal inflammatory response syndrome (FIRS) is a systemic inflammatory response caused by the activation of the fetal immune system. The serological diagnostic criterion for fetal inflammatory response syndrome is a cord blood interleukin-6 concentration that exceeds 11 pg/mL, while pathologic evidence indicates the presence of funisitis or chorionic vasculitis. It can affect all systems of the fetus. Alterations in patients' hematopoietic system are primarily reflected by changes in peripheral blood leukocyte and neutrophil counts.
CASE PRESENTATION: We performed placental pathology to identify FIRS and showed two cases of neonatal leukemoid reaction caused by FIRS. These two babies' alterations in hematopoietic system resolves spontaneously with the inflammation relief, without specific interventions. During the 16‑month and14- month follow‑up period, their motor and intellectual development was normal.
CONCLUSIONS: . Neonatal leukemoid reaction is a reactive disease characterized by abnormal blood parameters similar to those of leukemia, but not leukemia. It is an aberrant hematopoietic response that typically resolves spontaneously with cause relief without requiring specific interventions.
The invention discloses a pharmaceutical composition, and a preparation method, a preparation and application thereof. The pharmaceutical composition comprises the following bulk drugs by weight: 15 to 24 parts of taxillus, 15 to 24 parts of Radix Astragali, 10 to 15 parts of prepared fleece flower root, 8 to 15 parts of raw white peony root, 12 to 18 parts of stir-fried eucommia bark, 8 to 12 parts of Chinese angelica, 3 to 8 parts of Ligusticum wallichii, 8 to 12 parts of red sage root, 8 to 12 parts of gastrodia tuber, 15 to 20 parts of uncaria and 15 to 20 parts of fleeceflower stem. The pharmaceutical composition is prepared through extraction, concentration and drying. The preparation method comprises the following steps: pretreatment, extraction, concentration and drying. The preparation is a tablet, powder, oral liquid, capsule, granule, pill or honeyed pill prepared from the pharmaceutical composition and pharmaceutically acceptable adjuvant. The pharmaceutical composition is applied to preparation of drugs used for treating hypertension and target-organ damages caused by hypertension, e.g., cerebrovascular diseases, hypertensive heart diseases and hypertensive renal damage. Through combination and cooperation of the bulk drugs of the pharmaceutical composition, the pharmaceutical composition is capable of nourishing yin at first and reducing yang next, enables the kidney and brain to be nourished and the liver to be calmed, nourishes the liver and the kidney, extinguishes wind and dredges collaterals; so high blood pressure is lowered.
SCOPE: Processing of whey protein concentrate (WPC) for infant formulas may induce protein modifications with severe consequences for preterm newborn development. The study investigates how conventional WPC and a gently processed skim milk-derived WPC (SPC) affect gut and immune development after birth.
METHODS AND RESULTS: Newborn, preterm pigs used as a model of preterm infants were fed formula containing WPC, SPC, extra heat-treated SPC (HT-SPC), or stored HT-SPC (HTS-SPC) for 5 days. SPC contained no protein aggregates and more native lactoferrin, and despite higher Maillard reaction product (MRP) formation, the clinical response and most gut and immune parameters are similar to WPC pigs. SPC feeding negatively impacts intestinal MRP accumulation, mucosa, and bacterial diversity. In contrast, circulating T-cells are decreased and oxidative stress- and inflammation-related genes are upregulated in WPC pigs. Protein aggregation and MRP formation increase in HTS-SPC, leading to reduced antibacterial activity, lactase/maltase ratio, circulating neutrophils, and cytotoxic T-cells besides increased gut MRP accumulation and expression of TNFAIP3.
CONCLUSION: The gently processed SPC has more native protein, but higher MRP levels than WPC, resulting in similar tolerability but subclinical adverse gut effects in preterm pigs. Additional heat treatment and storage further induce MRP formation, gut inflammation, and intestinal mucosal damage.
The desirable serum lithium levels are 0.6 to 1.2 mEq/L. Dosage will vary from one individual to another, but usually 300 mg of Lithium Carbonate t.i.d. or q.i.d. will maintain this level. Serum lithium levels in uncomplicated cases receiving maintenance therapy during remission should be monitored at least every two months.

Patients abnormally sensitive to lithium may exhibit toxic signs at serum levels of 1 to 1.5 mEq/L. Elderly patients often respond to reduced dosage, and may exhibit signs of toxicity at serum levels ordinarily tolerated by other patients.
Statins are one of the lipid lowering drugs that help in reducing cholesterol levels in the body by specifically inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase; which is a rate limiting enzyme for cholesterol synthesis. Rosuvastatin (RSV) and atorvastatin (ATV) have shown to have bone stimulatory and anti-inflammatory effects.. The present study aims to explore the efficacy of 1.2% RSV and 1.2% ATV gel as a local drug delivery and redelivery system as an adjunct to scaling and root planing (SRP) for the treatment of degree II furcation defects.

Methods: Ninety patients with mandibular buccal class II furcation defects were randomly allocated into three treatment groups: SRP plus placebo gel (group 1), SRP plus 1.2% RSV gel (group 2) and 1.2% ATV gel (group3). Clinical and radiographic parameters were recorded at baseline then after 6 months. The gels were redelivered at the respective sites at this 6 month appointment. Then again all clinical and radiographic parameters were recorded after 3 months. (9 months from baseline)
Natural rare sugars are an alternative category of sweeteners with positive physiologic and metabolic effects both in in vitro and animal models. D-allulose is a D-fructose epimer that combines 70% sucrose sweetness with the advantage of an extremely low energy content. However, there are no data about the effect of D-allulose against adipose dysfunction; thus, it remains to be confirmed whether D-allulose is useful in the prevention and in treatment of adipose tissue alterations. With this aim, we evaluated D-allulose's preventive effects on lipid accumulation in 3T3-L1 murine adipocytes exposed to palmitic acid (PA), a trigger for hypertrophic adipocytes. D-allulose in place of glucose prevented adipocyte hypertrophy and the activation of adipogenic markers C/EBP-β and PPARγ induced by high PA concentrations. Additionally, D-allulose pretreatment inhibited the NF-κB pathway and endoplasmic reticulum stress caused by PA, through activation of the Nrf2 pathway. Interestingly, these effects were also observed as D-allulose post PA treatment. Although our data need to be confirmed through in vivo models, our findings suggest that incorporating D-allulose as a glucose substitute in the diet might have a protective role in adipocyte function and support a unique mechanism of action in this sugar as a preventive or therapeutic compound against PA lipotoxicity through the modulation of pathways connected to lipid transport and metabolism.
PURPOSE:Mixed powder easily usable as a healthy food without requiring hands, providing hard tablets, not causing change in quality, scattering, and residue of powder of organism component, containing the powder of organism component having a large amount of fats and oils, an oil-absorbing excipien, and crystalline cellulose. CONSTITUTION:Mixed powder comprising powder of organism component containing a larg amount of fats and oils or purified oil as an active ingredient, and at least an oil-absorbing excipien and crystalline cellulose. The powder of organism component, for example, consists of seed, germ, bud, flower, or root of plant such as nutmeg tree, rutaecarpa Hook. fil et Thoms., sandalwood, etc., or organs or line of animal liver of musk, etc. Magnesium metasilicate aluminate, hydrotalcide, etc. may be cited as the oil-absorbing excipien, and an amount of it added is about 1.5-3pts.wt. based on 1pt.wt. extract with ethyl ether in the powder of organism component. An amount of the crystalline cellulose is preferably the same amount as that of the oil-absorbing excipien.
Agents for dyeing keratin fibres, in particular human hair, wherein said agents are produced by mixing (A) one or more oxidation dye precursors in salt form and (B) one or more water-soluble salts of barium or of calcium, wherein the molar ratio (A)/(B), is between 1.0-1.4. Preferably, the oxidation dye precursors are in the form of sulfate salts and the calcium or barium salts are selected from barium hydroxide, barium chloride, barium carbonate, barium hydrogen carbonate, barium nitrate, barium bromide, barium acetate, calcium hydroxide, calcium chloride, calcium nitrate, calcium bromide or calcium acetate. Preferably the agent is in the form of an oil-in-water emulsion. Kits containing the agent and a peroxide developer composition are also disclosed. In an embodiment the dye precursor is p-toluene diamine sulfate and the salt is barium hydroxide. In another embodiment, a developer type dye is used in its salt from and this reacts in-situ with the barium or calcium salt to yield the free base form of the dye precursor and the exchange salt of the barium or calcium salt.
The invention discloses a preparation method of a novel cytokine fusion protein-chemokine interferon inducible protein 10 single-chain antibody (IP10-scFv). The method comprises the steps of: S1. synthesizing a human IP10 extracellular terminal gene; S2. utilizing a recombinant phage antibody system to construct the single-chain antibody of an anti-epidermal growth factor receptor mutant III (EGFRvIII); S3. conducting optimization synthesis on a (Gly4Ser)3 flexible joint; S4. cloning IP10 and the anti-EGFRvIII single-chain antibody into an eukaryotic expression vector, and conducting connection through the optimized (Gly4Ser)3 flexible joint, thus obtaining an IP10-scFv gene; and S5. subjecting the gene to high expression in Escherichia coli, thus obtaining IP10-scFv with biological activity. The IP10-scFv provided in the invention has a higher antigen-antibody binding rate, can reduce the dosage of IP10 clinically and reduce the toxic and side effects, and further can reduce the adoptive input amount of glioma specific cytotoxic T lymphocyte (CTL) and increase the activity of CTL.
FIELD: virology, biotechnology. SUBSTANCE: invention relates to culturing cells and tissues for preparing and study of viruses. The strain of cells PK-15/B5 is obtained by cloning piglet kidney cellular line PK-15 by method of limiting dilution and passage in Eagle's MEM medium with 5% of calve fetal serum blood or newborn calve serum blood. Karyotype is stable for 50 passages. Modal class is represented by cells containing 31 chromosome (61%). Cell culture PK-15/B5 is sensitive to different strains of classic swine plague and represents the test-system used in diagnosis and titration of classic swine plague virus. Invention allows to obtain the strain of piglet kidney transplantable cells PK-15/B5 that is stable by biological indices and useful for science-research and diagnostic aims. EFFECT: valuable properties of strain. 1 tbl
They take the three times of the ultrasonography-guided injections for four weeks(0,2,4 weeks) under double-blind. Dextrose group as active control group takes the 3ml-15%-dextrose solution for same procedure: the lesion( tear or tendinosis about extensor carpi radialis brevis, extensor digitorum communis, radial collateral ligament ) of lateral epicondylitis for 4 weeks. This dextrose solution for common extensor tendons are used as prolotherapy.
A plurality of remote terminals (A) are each disposed in a physician's office and are connected by telephone lines or other electronic data communication with a central processing system (B). Each terminal includes a data entry key board (10) and a magnetic tape reader (12) for entering physician, patient, medical service, insurance, and other medically related data. The entered data is processed by a terminal processor (20) to incorporate previously stored data from an electronic data memory and to transfer and store entered medical transaction data to memory. The central processing system includes a physician file for storing participating physician identifications for verifying received physician information data, a patient memory for storing participating patient data for verifying received patient identification data, an insurance company file for storing appropriate format for medical claims for each of a plurality of participating insurance companies, and a claims file for storing a record of medical insurance claims processed. A central processing computer processes the received data and formats it into the approriate format for a medical claim to the identified insurance company. A printer (D) or an electronic data transfer (C) transfers the medical claims from the central processing system directly to the insurance companies. Electronic funds transfer facilities at the central processing station and at one or more banks or financial institutions are called upon to transfer funds directly to a physician's account and to acknowledge receipt of funds from insurance company accounts.
BACKGROUND: Environmental bacteria in animal healthcare facilities may constitute a risk for healthcare-associated infections (HAI). Knowledge of the bacterial microflora composition and factors influencing the environmental bacterial load can support tailored interventions to lower the risk for HAI. The aims of this study were to: (1) quantify and identify environmental bacteria in one operating room (OR) and one ultrasound room (UR) in a small animal hospital, (2) compare the bacterial load to threshold values suggested for use in human healthcare facilities, (3) characterise the genetic relationship between selected bacterial species to assess clonal dissemination, and (4) investigate factors associated with bacterial load during surgery. Settle plates were used for passive air sampling and dip slides for surface sampling. Bacteria were identified by Matrix Assisted Laser Desorption-Time Of Flight. Antimicrobial susceptibility was determined by broth microdilution. Single nucleotide polymorphism-analysis was performed to identify genetically related isolates. Linear regression was performed to analyse associations between observed explanatory factors and bacterial load.
RESULTS: The bacterial load on settle plates and dip slides were low both in the OR and the UR, most of the samples were below threshold values suggested for use in human healthcare facilities. All settle plates sampled during surgery were below the threshold values suggested for use in human clean surgical procedures. Staphylococcus spp. and Micrococcus spp. were the dominating species. There was no indication of clonal relationship among the sequenced isolates. Bacteria carrying genes conveying resistance to disinfectants were revealed. Air change and compliance with hygiene routines were sufficient in the OR. No other factors possibly associated with the bacterial load were identified.
CONCLUSIONS: This study presents a generally low bacterial load in the studied OR and UR, indicating a low risk of transmission of infectious agents from the clinical environment. The results show that it is possible to achieve bacterial loads below threshold values suggested for use in human healthcare facilities in ORs in small animal hospitals and thus posing a reduced risk of HAI. Bacteria carrying genes conveying resistance to disinfectants indicates that resistant bacteria can persist in the clinical environment, with increased risk for HAI.
PURPOSE:To provide a poultice usable also as a bandage, having air-permeability as well as the capability of stably keeping the diseases part, and effective to the remedy of sprain and bruise, by applying the poultice drug to a substrate having a number of mesh pores and stretchable along longitudinal direction. CONSTITUTION:For example, the poultice drug layer 2 is applied to the surface of a longitudinally stretchable substrate 1 having a number of pores of proper mesh, and is coated with a release film 2 to keep the adhesivity of the poultice layer. The obtained laminate is slit to the width of a bandage to obtain the objective product. It is supplied in a continuous form having a proper length without cutting into separate pieces. The substrate is made of a combined yarn of rayon and polyester, and a stretchable nonwoven cloth is most suitable in veiw of the drug-holding performance and the feeling to the skin. The width of the bandage is determined with reference to the official standard of the width of bandage. It has higher air-permeability and stretchability than conventional poultice, and has excellent effect to mitigate the local inflammation.